| Document Date: 2014-10-27 08:46:15
Open Document File Size: 97,71 KBShare Result on Facebook
City Manchester / / Company September 9th 2014 F2G Limited / F2G Ltd / / Country United Kingdom / / Currency USD / GBP / / / Event Funding / FDA Phase / / IndustryTerm treatment of serious fungal disease / / MedicalCondition invasive aspergillosis / systemic fungal infections / allergies / serious fungal disease / fungal infections / asthma / / MedicalTreatment oral therapy / / Organization Department for Business / Innovation and Skills / Technology Strategy Board / / Person Mike Birch / Ian Nicholson / / / Position Chief Operating Officer / CEO / / Product F901318 / F2G / / Technology Biotechnology / / URL www.innovateuk.org/-/catalysts / www.innovateuk.org / www.f2g.com / / |
PRESS RELEASE Issued: Manchester, September 9th 2014 F2G Limited, the UK-based antifungal drug discovery and development company, today announced a major funding award from the Technology Strategy Board’s Biomedical C